Fibromyalgia – Unmet Need – Unmet Need – Fibromyalgia (US/EU)
Fibromyalgia is a chronic condition characterized by pain, tenderness throughout the body, fatigue, and disrupted sleep. Most diagnosed fibromyalgia patients receive prescription drug treatment with FDA approved therapies (i.e., pregabalin, duloxetine, milnacipran) or off-label therapies (e.g., gabapentin, cyclobenzaprine, tramadol); these therapies are largely generic antiepileptic drugs (AEDs), antidepressants, or muscle relaxants. However, a sizable percentage of fibromyalgia patients do not receive adequate symptom relief, underscoring the need for improved treatment options for core symptoms and common comorbidities (e.g., anxiety, depression). Well-tolerated, effective novel drugs to manage this disease hold significant commercial opportunity in the large fibromyalgia population. Data and insights from this report will elucidate key areas of potential differentiation for developers of emerging agents.
Questions answered
- What are surveyed rheumatologists’ opinions about the relative performance of key current therapies (e.g., duloxetine, pregabalin, milnacipran) on clinical attributes?
- What are the top areas of unmet need and opportunity in fibromyalgia?
- Based on the responses of surveyed physicians, what is the level of unmet need for key clinical attributes?
- Based on a conjoint analysis and TPP simulation, what trade-offs across different clinical attributes and price are acceptable to rheumatologists for a hypothetical new fibromyalgia drug?
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 30 European rheumatologists fielded in June 2024
Key drugs: Pregabalin, duloxetine, tramadol IR, gabapentin, milnacipran
Product description
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP Simulator.
Key feature
The Target Product Profile (TPP) Simulator tool allows for customizable market simulations based on conjoint analysis that depicts how physicians make decisions based on actual behavior rather than opinion. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
